Chris O’Dell, SVP of market solutions at Turquoise Health, discusses the potential impact of DTC programs on the drug-pricing system.
Complexity is the enemy here. The fact that no one knows what a drug is going to cost them before they get it is clearly a problem in the US.
According to Chris O’Dell, DTC programs may have a limited impact in the near term, but he is optimistic about their long-term effects.
Author's summary: DTC programs may simplify drug pricing.